Business Wire

Catalysis Launches New European CEO Forum to Enhance Focus on Lean Healthcare Transformation

Del

Catalysis today announced the creation of a new peer-to-peer network for healthcare senior executives. The new European CEO Forum is designed for hospital executives who are involved in organizational transformation using lean methodology. The European CEO Forum is organized and led by Helen Zak, president of International Strategy and Relations at Catalysis.

“We’re excited to further our presence in Europe with the launch of the CEO Forum,” said Zak, who, in 2015, launched and led a similar program for healthcare executives in the United States. “Lean transformations are hard work and you need the support of others on the same journey. The CEO Forum provides an ongoing program where senior executives can learn, share and connect with each other to move beyond individual learning to interdependent learning.”

Founding members of the European CEO Forum include leaders from St. Antonius (The Netherlands), CHU UCL Namur (Belgium), Region Hovedstadens Psykiatri (Denmark), NHS Highland (Scotland), NHS Western Sussex (United Kingdom), University Hospital of Helsinki (Finland), NHS Berkshire Trust (United Kingdom), University Hospital of North Norway (Norway), and Spital Mannedorf AG (Switzerland).

Members of the European CEO Forum convene throughout the year to learn about tools, systems and principles that lead to a successful lean transformation. They receive feedback, reflect on progress made, and create and update plans developing themselves, their teams and their organizations.

“The European CEO Forum is the ideal program for senior executives who are focused on transforming their healthcare organizations,” said Marianne Griffiths, CEO of NHS Western Sussex Hospitals, United Kingdom. “Sharing best practices and learning how to advance the lean transformation process is invaluable to our success. I’m pleased to be part of such a useful forum.”

Some of the work and results already made by members of the CEO Forum will be showcased at the 4th Lean Healthcare Transformation Summit - Europe, Oct. 9-10 in Amsterdam. To register or learn more about the Summit, visit https://createvalue.org/events-around-the-world/summit-eu/

About Catalysis

Catalysis inspires healthcare leaders and accelerates change. With a focus on experiential education, Catalysis helps healthcare leaders in the United States and Europe create transformative change designed around the patient, payment and incentives based on value and outcomes, and transparency of performance (quality and cost). Founded in 2008, Catalysis is a not for profit whose mission is to help create more healthcare value in the industry. Learn more at: createvalue.org and follow us on Twitter @hcvalue.

Contact information

Catalysis
Sara Thompson, 920-659-7461
sthompson@createvalue.org

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Illumina and the Lundbeck Foundation GeoGenetics Centre Collaborate to Generate One of the Largest Ancient Genome Datasets to Decode the Genetic Origins and Evolution of Mental Health Issues26.3.2019 06:00:00 CETPressemelding

Illumina (NASDAQ:ILMN) and the Lundbeck Foundation GeoGenetics Centre at the University of Copenhagen, Denmark partner to explore the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens. One of the first projects of its kind worldwide, the endeavor aims to acquire new knowledge in terms of the medical and biological understanding of special factors underlying the development of human neuropsychiatric diseases through the ages. Ultimately, the project may provide a new approach to the development of medicines and other therapeutic treatments for mental and neurological conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005867/en/ Where do brain disorders come from? In an effort to shed light on the role of microbes in the pathogenesis of neuropsychiatric illnesses, such as Alzheimer’s disease and schizophrenia, Professor Eske Willerslev and his team

Earth Networks Announces Completion of Severe Weather Early Warning System for PAGASA25.3.2019 23:00:00 CETPressemelding

Earth Networks announced today the completion of the Philippines’ first nationwide severe weather monitoring and alerting network with associated software services for the Philippine Atmospheric, Geophysical, and Astronomical Services Administration (PAGASA), the National Meteorological and Hydrological Services (NMHS) agency of the Republic of the Philippines. The announcement was made at the 6th annual InterMET Asia conference in Singapore. Initiated in 2017, and formally commissioned this week, the technology partnership between PAGASA and Earth Networks is the first of its kind in the Philippines and surrounding regions, powered by a network of total lightning sensors and real-time automatic weather stations for mesoscale monitoring. Installed and operated together with Philippines partner West Point Engineering, the 10-year program includes: Real-time lightning detection powered by the Earth Networks Total Lightning Network On-the-ground weather monitoring via the Earth Networks W

Game of Thrones Winter is Coming™ Launches Worldwide25.3.2019 23:00:00 CETPressemelding

Yoozoo Games, a leading game developer and publisher, today announced the global launch of Game of Thrones Winter is Coming™ , a real-time strategy PC browser game officially licensed by Warner Bros. Interactive Entertainment under license from HBO®. The game is now available in English, with additional languages to follow. HBO, Warner Bros. Interactive Entertainment and Yoozoo Games have collaborated to recreate Westeros on a massive scale, delivering an authentic and immersive multiplayer world laid out across the Seven Kingdoms – complete with major landmarks and castles from the epic TV series. The story begins immediately following the death of Eddard Stark, when the player emerges as a new Westeros lord or lady in his stead. Strategising starts in earnest in Game of Thrones Winter is Coming as players aim to build an impenetrable base, train a victorious army and recruit faithful followers from a pool of iconic characters. As players progress, they must continue to acquire the mi

bluebird bio Statement on European Regulatory Status of LentiGlobin™25.3.2019 22:40:00 CETPressemelding

A third party press release was issued today stating that the EMA (European Medicines Agency) issued an approval for the conditional Marketing Authorization Application (MAA) for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia (TDT). LentiGlobin for TDT is scheduled to be reviewed as part of the CHMP (Committee on Human Medicinal Products) meeting from March 25 – 28, however no opinion has been issued by the CHMP. If the CHMP’s opinion is issued it would then be reviewed by the European Commission (EC), which has the authority to grant approval for the use of LentiGlobin in the EU. About bluebird bio, Inc. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working

Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis25.3.2019 20:30:00 CETPressemelding

Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). The pivotal efficacy and safety data provided in the application result from the SUNBEAM™ and RADIANCE™ Part B phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trials. “New oral treatment options with differentiated profiles like ozanimod are needed to help address an unmet need for people with relapsing forms of MS,” said Jay Backstrom, M.D., Chief Medical Officer for Celgene. “With concurrent applications in the U.S. and EU, we look forward to advancing this promising medicine through the regulatory review process to provide a new option for the treatment of RMS in

AVLT and UKTS Announce the European Medicines Agency’s Approval of the Conditional Marketing Authorization Application for Zynteglo™ (Previously Known as Lentiglobin™) Gene Therapy for the Treatment of Transfusion Dependent Beta Thalassaemia25.3.2019 19:50:00 CETPressemelding

Associazione Veneta Lotta alla Talassemia (AVLT) and the UK Thalassaemia Society (UKTS) announced today that the European Medicines Agency (EMA) has approved bluebird bio’s application for Conditional Marketing Authorization (cMAA) of their product Zynteglo™, a gene therapy for the treatment of adolescents and adults with transfusion-dependent β-thalassaemia (TDT) who do not have a β0/β0 genotype. As a result of this marketing authorisation, Zynteglo™ is now approved for use in all European countries covered by the European Medicines Agency. Zynteglo™ has been given ‘conditional authorisation’. This means that there is more evidence to be submitted, which the company is required to provide under specific obligations. Every year, the EMA will review any new information that becomes available. “People living with transfusion-dependent β-thalassaemia have a reduced life expectancy, requiring life-long frequent blood transfusions that are life-saving but may lead to complications, includin